🎉 M&A multiples are live!
Check it out!

Vericel Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vericel and similar public comparables like Cynata Therapeutics, Aroa Biosurgery, and Lineage Cell Therapeutics.

Vericel Overview

About Vericel

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.


Founded

1989

HQ

United States of America
Employees

357

Website

vcel.com

Financials

LTM Revenue $251M

LTM EBITDA $59.1M

EV

$2.0B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Vericel Financials

Vericel has a last 12-month revenue of $251M and a last 12-month EBITDA of $59.1M.

In the most recent fiscal year, Vericel achieved revenue of $237M and an EBITDA of $16.6M.

Vericel expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Vericel valuation multiples based on analyst estimates

Vericel P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $198M $237M XXX XXX XXX
Gross Profit $110M $136M XXX XXX XXX
Gross Margin 56% 57% XXX XXX XXX
EBITDA $2.9M $16.6M XXX XXX XXX
EBITDA Margin 1% 7% XXX XXX XXX
Net Profit -$16.7M -$3.2M XXX XXX XXX
Net Margin -8% -1% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Vericel Stock Performance

As of April 15, 2025, Vericel's stock price is $41.

Vericel has current market cap of $2.1B, and EV of $2.0B.

See Vericel trading valuation data

Vericel Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.0B $2.1B XXX XXX XXX XXX $0.24

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Vericel Valuation Multiples

As of April 15, 2025, Vericel has market cap of $2.1B and EV of $2.0B.

Vericel's trades at 8.2x LTM EV/Revenue multiple, and 34.7x LTM EBITDA.

Analysts estimate Vericel's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Vericel and 10K+ public comps

Vericel Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.0B XXX XXX XXX
EV/Revenue 8.6x XXX XXX XXX
EV/EBITDA 123.3x XXX XXX XXX
P/E 199.5x XXX XXX XXX
P/E/Growth 2.1x XXX XXX XXX
EV/FCF -352.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vericel Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Vericel Valuation Multiples

Vericel's NTM/LTM revenue growth is 22%

Vericel's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.5M for the same period.

Over next 12 months, Vericel's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Vericel's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Vericel and other 10K+ public comps

Vericel Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 20% XXX XXX XXX XXX
EBITDA Margin 7% XXX XXX XXX XXX
EBITDA Growth 481% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 29% XXX XXX XXX XXX
Revenue per Employee $0.7M XXX XXX XXX XXX
Opex per Employee $0.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 10% XXX XXX XXX XXX
Opex to Revenue 71% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Vericel Public Comps

See public comps and valuation multiples for Regenerative Medicine and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Vericel M&A and Investment Activity

Vericel acquired  XXX companies to date.

Last acquisition by Vericel was  XXXXXXXX, XXXXX XXXXX XXXXXX . Vericel acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Vericel

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Vericel

When was Vericel founded? Vericel was founded in 1989.
Where is Vericel headquartered? Vericel is headquartered in United States of America.
How many employees does Vericel have? As of today, Vericel has 357 employees.
Who is the CEO of Vericel? Vericel's CEO is Mr. Dominick C. Colangelo.
Is Vericel publicy listed? Yes, Vericel is a public company listed on NAS.
What is the stock symbol of Vericel? Vericel trades under VCEL ticker.
When did Vericel go public? Vericel went public in 1997.
Who are competitors of Vericel? Similar companies to Vericel include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of Vericel? Vericel's current market cap is $2.1B
What is the current revenue of Vericel? Vericel's last 12-month revenue is $251M.
What is the current EBITDA of Vericel? Vericel's last 12-month EBITDA is $59.1M.
What is the current EV/Revenue multiple of Vericel? Current revenue multiple of Vericel is 8.2x.
What is the current EV/EBITDA multiple of Vericel? Current EBITDA multiple of Vericel is 34.7x.
What is the current revenue growth of Vericel? Vericel revenue growth between 2023 and 2024 was 20%.
Is Vericel profitable? Yes, Vericel is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.